Surgery in Stage IV Breast Cancer

  • The role of locoregional treatment in the setting of de novo metastatic breast cancer:
    • Is controversial
  • Typically, surgery has been reserved for:
    • Palliation
  • A 2012 meta-analysis of 15 retrospective studies:
    • Showed resection of the primary tumor was associated with:
      • Increased overall survival:
        • OS; HR 0.69, 95% CI 0.63 to 0.77, P<0.00001
  • Unfortunately, recent prospective studies have shown conflicting results:
    • A Turkish study showed improved survival at a median of 40 months follow-up:
      • Especially in more indolent forms of breast cancer
    • In contrast, a U.S. study did not show improvement in survival associated with surgery
  • Determinants of improved survival:
    • Were related to response to therapy
  • An Italian study showed:
    • Improvement in survival:
      • In patients with HER2 positive disease after first-line trastuzumab-based therapy
  • In addition, an Indian study by Badwe et al:
    • Did not show a survival advantage with resection of the primary cancer:
      • At a median follow-up of 23 months:
        • The overall survival was 41.9% in the locoregional surgical arm vs. 43.0% in the non-locoregional treatment arm
  • Each of these studies has potential bias flaws:
    • But show potential benefit of resection:
      • In select patients with:
        • High functional status and good response to optimal systemic therapy
  • While awaiting the results of ECOG E2108 clinical trial:
    • Surgery in stage IV breast cancer:
      • Patients should be discussed in a multidisciplinary setting, taking into account:
        • Comorbidities, response to therapy, and tumor burden
  • References
    • Poggio F, Lambertini M, de Azambuja E. Controversies in oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? ESMO Open 2018;3:e000324.
    • Wu SG, Zhang WW, Sun JY, et al. The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis. Oncotarget. 2017;8(40):67851-67860. Published 2017 Jun 29.
    • Soran A, Ozmen V, Ozbas S, et al. randomized trial comparing resection of primary tumor with no surgery in Stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol. 2018;25(11): 3141-3149.
    • R Badwe, R Hawaldar, N Nair, et al.: Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380-1388.

#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #BreastCancer #CASO #CenterforAdvancedSurgicalOncology #Miami

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s